Taysha (TSHA) Insider Files Form 144 for 10,770 Shares
Rhea-AI Filing Summary
Taysha Gene Therapies (TSHA) filing a Form 144 notifies the planned sale of 10,770 shares of common stock through Maxim Group on Nasdaq with an aggregate market value of $30,479.10. The shares were acquired and vested as RSU awards on 09/22/2025 and settled in stock as consideration for the reporting person’s service. The filing shows 272,794,885 shares outstanding and reports no other sales in the past three months. The filer certifies no undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale disclosure of vested RSUs; transaction size is immaterial to total shares outstanding.
The Form 144 documents a planned sale of 10,770 shares via a broker on Nasdaq, stemming from RSUs that vested and were settled in stock on the same date. With 272.8 million shares outstanding, the position represents roughly 0.0039% of the outstanding stock, indicating limited direct market impact. The filing includes the required certification regarding material nonpublic information.
TL;DR: Standard disclosure consistent with Rule 144 procedures following RSU vesting and settlement.
The notice provides the broker name, exact share count, acquisition and planned sale date, and nature of acquisition (RSU award). It confirms no sales in the prior three months and includes the statutory signature caution, fulfilling disclosure obligations under the rule. No governance or compliance issues are evident from the content provided.